| VEGF inhibition and renal thrombotic microangiopathy V Eremina, JA Jefferson, J Kowalewska, H Hochster, M Haas, J Weisstuch, ... New England Journal of Medicine 358 (11), 1129-1136, 2008 | 1683 | 2008 |
| Randomized trial of TAS-102 for refractory metastatic colorectal cancer RJ Mayer, E Van Cutsem, A Falcone, T Yoshino, R Garcia-Carbonero, ... New England Journal of Medicine 372 (20), 1909-1919, 2015 | 1389 | 2015 |
| Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study HS Hochster, LL Hart, RK Ramanathan, BH Childs, JD Hainsworth, ... Journal of Clinical Oncology 26 (21), 3523-3529, 2008 | 957 | 2008 |
| NCCN guidelines insights: colon cancer, version 2.2018 AB Benson, AP Venook, MM Al-Hawary, L Cederquist, YJ Chen, ... Journal of the National Comprehensive Cancer Network 16 (4), 359-369, 2018 | 871 | 2018 |
| Rectal cancer, version 2.2018, NCCN clinical practice guidelines in oncology AB Benson, AP Venook, MM Al-Hawary, L Cederquist, YJ Chen, ... Journal of the National Comprehensive Cancer Network 16 (7), 874-901, 2018 | 865 | 2018 |
| Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a … AP Venook, D Niedzwiecki, HJ Lenz, F Innocenti, B Fruth, JA Meyerhardt, ... Jama 317 (23), 2392-2401, 2017 | 825 | 2017 |
| A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. C Jacobs, G Lyman, E Velez-García, KS Sridhar, W Knight, H Hochster, ... Journal of Clinical Oncology 10 (2), 257-263, 1992 | 822 | 1992 |
| Colon cancer, version 1.2017, NCCN clinical practice guidelines in oncology AB Benson, AP Venook, L Cederquist, E Chan, YJ Chen, HS Cooper, ... Journal of the National Comprehensive Cancer Network 15 (3), 370-398, 2017 | 759 | 2017 |
| Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma M Tempero, W Plunkett, V Ruiz van Haperen, J Hainsworth, H Hochster, ... Journal of Clinical Oncology 21 (18), 3402-3408, 2003 | 600 | 2003 |
| CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts … AP Venook, D Niedzwiecki, HJ Lenz, F Innocenti, MR Mahoney, BH O'Neil, ... Journal of Clinical Oncology 32 (15_suppl), LBA3-LBA3, 2014 | 559 | 2014 |
| Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study LB Saltz, HJ Lenz, HL Kindler, HS Hochster, S Wadler, PM Hoff, ... Journal of Clinical Oncology 25 (29), 4557-4561, 2007 | 522 | 2007 |
| Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with … E Poplin, Y Feng, J Berlin, ML Rothenberg, H Hochster, E Mitchell, ... Journal of clinical oncology 27 (23), 3778-3785, 2009 | 520 | 2009 |
| Impact of primary (1º) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB … AP Venook, D Niedzwiecki, F Innocenti, B Fruth, C Greene, BH O'Neil, ... Journal of Clinical Oncology 34 (15_suppl), 3504-3504, 2016 | 485 | 2016 |
| ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. JL Speyer, MD Green, A Zeleniuch-Jacquotte, JC Wernz, M Rey, J Sanger, ... Journal of Clinical Oncology 10 (1), 117-127, 1992 | 427 | 1992 |
| Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study MS Lee, BY Ryoo, CH Hsu, K Numata, S Stein, W Verret, SP Hack, ... The Lancet Oncology 21 (6), 808-820, 2020 | 424 | 2020 |
| Cancer stem cells: the promise and the potential JA Ajani, S Song, HS Hochster, IB Steinberg Seminars in oncology 42, S3-S17, 2015 | 342 | 2015 |
| Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III … H Hochster, E Weller, RD Gascoyne, TM Habermann, LI Gordon, T Ryan, ... Journal of Clinical Oncology 27 (10), 1607, 2009 | 326 | 2009 |
| ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper A Dasari, VK Morris, CJ Allegra, C Atreya, AB Benson III, P Boland, ... Nature reviews Clinical oncology 17 (12), 757-770, 2020 | 265 | 2020 |
| Phase IB/II randomized study of FOLFIRINOX plus pegylated recombinant human hyaluronidase versus FOLFIRINOX alone in patients with metastatic pancreatic adenocarcinoma: SWOG S1313 RK Ramanathan, SL McDonough, PA Philip, SR Hingorani, J Lacy, ... Journal of Clinical Oncology 37 (13), 1062, 2019 | 256 | 2019 |
| Improved long term survival after intracavitary interleukin‐2 and lymphokine‐activated killer cells for adults with recurrent malignant glioma RL Hayes, M Koslow, EM Hiesiger, KB Hymes, EJ Moore, DM Pierz, ... Cancer 76 (5), 840-852, 1995 | 250 | 1995 |
